Intérêt de l’immunochimiothérapie conventionnelle par rapport à l’intensification avec support de cellules souches autologues en consolidation du traitement des patientsatteints d’un Lymphome Cérébral Primitif. Essai de phase 3 (MATRix/IELSG43). Effects […]

Réf.HematoStat.net ; 2 (11) : V68 Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress. Robert A Ariëns and al. Res Pract Thromb Haemost. 2022 Jul 6;6(5):e12747. doi: 10.1002/rth2.12747.

Réf.HematoStat.net ; 2 (11) : V67 Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The […]

Réf.HematoStat.net ; 2 (11) : V66 Understanding COVID-19-associated coagulopathy. Ann-Katrin Wienkamp and al. Front Immunol. 2022 Aug 1;13:953129. doi: 10.3389/fimmu.2022.953129.

Réf.HematoStat.net ; 2 (11) : V65 Platelets in the NETworks interweaving inflammation and thrombosis  PMID: 35979369

Réf.HematoStat.net ; 2 (11) : V64 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Farge D and […]

Réf. :HematoStat.net ; 2 (12) : R58 Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, et al. Blood. […]

Réf. :HematoStat.net ; 2 (12) : R57 Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma.Ansell SM, Radford J, Connors JM, Długosz-Danecka M, Kim WS, Gallamini A, et […]

Réf. :HematoStat.net ; 2 (11) : R55 Incidence and prevalence of venous thromboembolism in chronic liver disease: A systematic review and meta-analysis. Incidence and prevalence of venous thromboembolism in chronic […]